Pharmacological inhibition of USP8/AKT alleviates MDA5‐driven autoimmunity, demonstrating the USP8‐MDA5 axis as a therapeutic target for autoimmune disorders linked to aberrant MDA5 activation. Here, AKT1 is linked to autoimmune disease.